MRI of the Liver With Eovist
Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)
Sponsor: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Terminated
Unable to meet enrollment expectations.
Other terminated trials from Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- ATRIAL FIBRILLATION · Phase PHASE3 · May 2024
- Adenocarcinoma of the Colon · Phase PHASE2 · Sep 2017
- Hepatocellular Carcinoma · Phase NA · Jun 2013
- Recurrent or Progressive Low-grade Glioma · Phase PHASE2 · Mar 2013
See all terminations from Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Other Hepatocellular Carcinoma trials with similar outcome
A observational or N/A phase clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Terminated NA
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.